Menorrhagia: An update

Acta Obstetricia et Gynecologica Scandinavica

Volumn 82, Issue 5, 2003, Pages 405-422

  Oehler, M K ^a   Rees, Margaret C P ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Hysterectomy; Intrauterine progestogens; Mefenamic acid; Menorrhagia; Tranexamic acid

Indexed keywords

ACETYLSALICYLIC ACID; ANTIFIBRINOLYTIC AGENT; CELECOXIB; DANAZOL; DICLOFENAC; DYDROGESTERONE; ETAMSYLATE; ETHINYLESTRADIOL; FLUFENAMIC ACID; FLURBIPROFEN; GESTAGEN; GESTRINONE; GONADORELIN DERIVATIVE; IBUPROFEN; INDOMETACIN; LEVONORGESTREL; MECLOFENAMIC ACID; MEDROXYPROGESTERONE ACETATE; MEFENAMIC ACID; MIFEPRISTONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; ROFECOXIB; SALICYLIC ACID DERIVATIVE; TRANEXAMIC ACID;

ACNE; BONE DEMINERALIZATION; BREAST TENDERNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CRYOSURGERY; CURETTAGE; ENDOMETRIUM BIOPSY; ENDOSCOPIC SURGERY; FEMALE; FIBRINOLYSIS; HEADACHE; HIRSUTISM; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYSTERECTOMY; HYSTEROSCOPY; LARYNX DISORDER; MAJOR CLINICAL STUDY; MENORRHAGIA; MENSTRUATION; META ANALYSIS; METRORRHAGIA; MICROWAVE RADIATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RADIOFREQUENCY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SPOTTING; TRANSVAGINAL ECHOGRAPHY; UTERINE ARTERY EMBOLIZATION; VAGINAL DRYNESS; WEIGHT GAIN;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIFIBRINOLYTIC AGENTS; CONTRACEPTIVES, ORAL, COMBINED; ENDOMETRIUM; FEMALE; HUMANS; HYSTERECTOMY; HYSTEROSCOPY; MENORRHAGIA; MENSTRUATION; PROGESTINS;

EID: 0037901189     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0412.2003.00097.x     Document Type: Review

References (181)

1. Royal College of Obstetricians and Gynaecologists. The Initial Management of Menorrhagia - Evidence Based Clinical Guidelines, no. 1 . London: RCOG Press, 1998.
2. Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss - a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966; 45: 320-51.
3. Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss and iron deficiency. Acta Med Scand 1966; 180: 639-50.
4. Rees MC. Role of menstrual blood loss measurements in management of complaints of excessive menstrual bleeding. Br J Obstet Gynaecol 1991; 98: 327-8.
5. Warner P, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray G. Referral for menstrual problems. cross sectional survey of symptoms, reasons for referral, and management. BMJ 2001; 323: 24-8.
6. Dilley A, Drews C, Miller C, Lally C, Austin H, Ramaswamy D et al. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol 2001; 97: 630-6.
7. Clarke A, Black N, Rowe P, Mott S, Howle K. Indications for and outcome of total abdominal hysterectomy for benign disease: a prospective cohort study. Br J Obstet Gynecol 1995; 102: 611-20.
8. Hagenfeldt K. The role of prostaglandins and allied substances in uterine haemostasis. Contraception 1987; 36: 23-35.
9. Rees MCP, Anderson ABM, Demers LM, Turnbull AC. Prostaglandins in menstrual fluid in menorrhagia and dysmenorrhoea. Br J Obstet Gynaecol 1984; 91: 673-80.
10. Rees MCP, Anderson ABM, Demers LM, Turnbull AC. Endometrial and myometrial prostaglandin release during menstrual cycle in relation to menstrual blood loss. J Clin Endocrinol Metab 1984; 58: 813-8.
11. Makarainen L, Ylikorkala O. Primary and myoma-associated menorrhagia: role of prostaglandins and effects of ibuprofen. Br J Obstet Gynaecol 1986; 93: 974-8.
12. Adelantado JM, Rees MCP, Lopez-Bernal A, Turnbull AC. Increased uterine prostaglandin E receptors in menorrhagic women. Br J Obstet Gynaecol 1988; 95: 162-5.
13. Gleeson N, Devitt M, Sheppard BL, Bonnar J. Endometrial fibrinolytic enzymes in women with normal menstruation and dysfunctional uterine bleeding. Br J Obstet Gynaecol 1993; 100: 768-71.
14. Chimbira TH, Anderson AB, Turnbull A. Relation between measured menstrual blood loss and patient's subjective assessment of loss, duration of bleeding, number of sanitary towels used, uterine weight and endometrial surface area. Br J Obstet Gynaecol 1980; 87: 603-9.
15. Haynes PJ, Hodgson H, Anderson AB, Turnbull AC. Measurement of menstrual blood loss in patients complaining of menorrhagia. Br J Obstet Gynaecol 1977; 84: 763-8.
16. Hallberg L, Nilsson L. Determination of menstrual blood loss. Scand J Clin Lab Invest 1964; 16: 244-8.
17. Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990; 97: 734-9.
18. Reid PC, Coker A, Coltart R. Assessment of menstrual blood loss using a pictorial chart: a validation study. BJOG 2000; 107: 320-2.
19. Fraser IS, Warner P, Marantos PA. Estimating menstrual blood loss in women with normal and excessive menstrual fluid volume Obstet Gynecol 2001; 98: 806-14.
20. Hope S. 10 minute consultation: menorrhagia. BMJ 2000; 321: 935.
21. Vercellini P, Cortesi I, Oldani S, Moschetta M, De Giorgi O, Crosignani PG. The role of transvaginal ultrasonography and outpatient diagnostic hysteroscopy in the evaluation of patients with menorrhagia. Hum Reprod 1997; 12: 1768-71.
22. Smith-Bindman R, Kerlikowske K, Feldstein VA, Subak L, Scheidler J et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA 1998; 280: 1510-7.
23. Dijkhuizen FP, Brolmann HA, Potters AE, Bongers MY, Heinz AP. The accuracy of transvaginal ultrasonography in the diagnosis of endometrial abnormalities. Obstet Gynecol 1996; 87: 345-9.
24. Tsuda H, Kawabata M, Yamamoto K, Inoue T, Umesaki N. Prospective study to compare endometrial cytology and transvaginal ultrasonography for identification of endometrial malignancies. Gynecol Oncol 1997; 65: 383-6.
25. RCOG. The Management of Menorrhagia in Secondary Care. Evidence-Based Guidelines 5, 1999.
26. Dijkhuizen FP, De Vries LD, Mol BW, Brolmann HA, Peters HM et al. Comparison of transvaginal ultrasonography and saline infusion sonography for the detection of intracavitary abnormalities in premenopausal women. Ultrasound Obstet Gynecol 2000; 15: 372-6.
27. Dueholm M, Forman A, Jensen ML, Laursen H, Kracht P. Transvaginal sonography combined with saline contrast sonohysterography in evaluating the uterine cavity in premenopausal patients with abnormal uterine bleeding. Ultrasound Obstet Gynecol 2001; 18: 54-61.
28. Kurjak A, Shalan H, Sosic A, Benic S, Zudenigo D et al. Endometrial carcinoma in postmenopausal women: evaluation by transvaginal color Doppler ultrasonography. Am J Obstet Gynecol 1993; 169: 1597-603.
29. Ballester MJ, Girones R, Torres JV, Guillen P, Osborne NG, Bonilla-Musoles F. Diagnosis of endometrial carcinoma: predictive value of transvaginal color Doppler. J Gynecol Surg 1994; 10: 173-83.
30. Aleem F, Predanic M, Calame R, Moukhtar M, Pennisi J. Transvaginal color and pulsed Doppler sonography of the endometrium: a possible role in reducing the number of dilatation and curettage procedures. J Ultrasound Med 1995; 14: 139-45; quiz 147-8.
31. Vuento MH, Pirhonen JP, Makinen JI, Tyrkko JE, Laippala PJ et al. Screening for endometrial cancer in asymptomatic postmenopausal women with conventional and colour Doppler sonography. Br J Obstet Gynaecol 1999; 106: 14-20.
32. Carter JR, Lau M, Saltzman AK, Hartenbach EM, Chen MD et al. Gray scale and color flow Doppler characterization of uterine tumors. J Ultrasound Med 1994; 13: 835-40.
33. Sheth S, Hamper UM, McCollum ME, Caskey CI, Rosenshein NB, Kurman RJ. Endometrial blood flow analysis in postmenopausal women: can it help differentiate benign from malignant causes of endometrial thickening? Radiology 1995; 195: 661-5.
34. Levine D. Pelvic Doppler. Semin Ultrasound CT MR 1999; 20: 239-49.
35. Perez-Medina T, Martinez O, Folgueira G, Bajo J. Which endometrial polyps should be resected? J Am Assoc Gynecol Laparosc 1999; 6: 71-4.
36. Farquhar CM, Lethaby A, Sowter M, Verry J, Baranyai J. An evaluation of risk factors for endometrial hyperplasia in premenopausal women with abnormal menstrual bleeding. Am J Obstet Gynecol 1999; 181: 525-9.
37. Bergman L, Beelen M, Gallee M, Hollema H, Benraadt J, van Leeuwen F. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. The Lancet 2000; 356: 881-7.
38. Balen A. Polycystic ovary syndrome and cancer. Hum Reprod Update 2001; 7: 522-5.
39. Spencer CP, Whitehead MI. Endometrial assessment re-visited. Br J Obstet Gynaecol 1999; 106: 623-32.
40. Emanuel MH, Wamsteker K, Lammes FB. Is dilatation and curettage obsolete for diagnosing intrauterine disorders in premenopausal patients with persistent abnormal uterine bleeding? Acta Obstet Gynecol Scand 1997; 76: 65-8.
41. Nagele F, O'Connor H, Davies A, Badawy A, Mohamed H, Magos A. 2500 outpatient diagnostic hysteroscopies. Obstet Gynecol 1996; 88: 87-92.
42. Stock RJ, Kanbour A. Prehysterectomy curettage. Obstet Gynecol 1975; 45: 537-41.
43. Bettochi S, Ceci O, Vicino M, Marello F, Impedovo L, Selvaggi L. Diagnostic approach of dilatation and curettage. Fertil Steril 2001; 75: 803-5.
44. Grimes DA. Diagnostic dilation and curettage: a reappraisal. Am J Obstet Gynecol 1982; 142: 1-6.
45. Guido RS, Kanbour-Shakir A, Rulin MC, Christopherson WA. Pipelle endometrial sampling: sensitivity in the detection of endometrial cancer. J Reprod Med 1995; 40: 553-5.
46. Manganiello PD, Burrows LJ, Dain BJ, Gonzalez J. Vabra aspirator and pipelle endometrial suction curette. A comparison. J Reprod Med 1998; 43: 889-92.
47. Dijkhuizen FP, Mol BW, Brolmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 2000; 89: 1765-72.
48. Feldman S, Shapter A, Welch WR, Berkowith RS. Two year follow-up of 263 patients with post/perimenopausal women vaginal bleeding and negative initial biopsy. Gynecol Oncol 1994; 55: 56-9.
49. Pasqualotto EB, Margossian H, Price LL, Bradley LD. Accuracy of preoperative diagnostic tools and outcome of hysteroscopic management of menstrual dysfunction. J Am Assoc Gynecol Laparosc 2000; 7: 201-9.
50. Mortakis AE, Mavrelos K. Transvaginal ultrasonography and hysteroscopy in the diagnosis of endometrial abnormalities. J Am Assoc Gynecol Laparosc 1997; 4: 449-52.
51. Torrejon R, Fernandez-Alba JJ, Carnicer I, Martin A, Castro C et al. The value of hysteroscopic exploration for abnormal uterine bleeding. J Am Assoc Gynecol Laparosc 1997; 4: 453-6.
52. Ben-Yehuda OM, Kim YB, Leuchter RS. Does hysteroscopy improve upon the sensitivity of dilatation of curettage in the diagnosis of endometrial hyperplasia or carcinoma? Gynecol Oncol 1998; 68: 4-7.
53. Kun K-Y, Lo L, Ho M-W, Tai C-M. A prospective randomised study comparing hysteroscopy and curettage (H & C) under local anaesthesia (LA) and general anaesthesia (GA) in Chinese population. J Obstet Gynaecol Res 1999; 25: 119-27.
54. Lo KW, Yuen PM. The role of outpatient diagnostic hysteroscopy in identifying anatomic pathology and histopathology in the endometrial cavity. J Am Assoc Gynecol Laparosc 2000; 7: 381-5.
55. Epstein E, Ramirez A, Skoog L, Valentin L. Transvaginal sonography, saline contrast sonohysterography and hysteroscopy for the investigation of women with postmenopausal bleeding and endometrium <5 mm. Ultrasound Obstet Gynecol 2001; 18: 157-62.
56. Brand A. Diagnosis of endometrial cancer in women with abnormal vaginal bleeding. J Soc Obstet Gynaecol Can 2000; 22: 102-4.
57. Arikan G, Reich O, Weiss U, Hahn T, Reinisch S et al. Are endometrial carcinoma cells disseminated at hysteroscopy functionally viable? Gynecol Oncol 2001; 83: 221-6.
58. Zerbe MJ, Zhang J, Bristow RE, Grumbine FC, Abularach S, Montz FJ. Retrograde seeding of malignant cells during hysteroscopy in presumed early endo-metrial cancer. Gynecol Oncol 2000; 79: 55-8.
59. Romano S, Shimoni Y, Muralee D, Shalev E. Retrograde seeding of endometrial carcinoma during hysteroscopy. Gynecol Oncol 1992; 44: 116-8.
60. Schmitz MJ, Nahhas WA. Hysteroscopy may transport malignant cells into the peritoneal cavity. Case report. Eur J Gynaecol Oncol 1994; 15: 121-4.
61. Rose PG, Mendelsohn G, Kornbluth I. Hysteroscopic dissemination of endometrial carcinoma. Gynecol Oncol 1998; 71: 145-6.
62. Egarter C, Krestan C, Kurz C. Abdominal dissemination of malignant cells with hysteroscopy. Gynecol Oncol 1996; 63: 143-4.
63. Coulter A, Long A, Kelland J, O'Meara S, Sculpher M et al. Managing menorrhagia. Qual Health Care 1995; 4: 218-26.
64. Coulter A, Kelland J, Peto V, Rees MC. Treating menorrhagia in primary care. An overview of drug trials and a survey of prescribing practice. Int J Technol Assess Health Care 1995; 11: 456-71.
65. Anderson AB, Haynes PJ, Guillebaud J, Turnbull AC. Reduction of menstrual blood-loss by prostaglandin-synthetase inhibitors. Lancet 1976; 1: 774-6.
66. Ylikorkala O, Pekonen F. Naproxen reduces idiopathic but not fibromyoma-induced menorrhagia. Obstet Gynecol 1986; 68: 10-2.
67. Lethaby A, Augood C, Duckitt K. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; 2: CD000400.
68. Cameron IT, Haining R, Lumsden MA, Thomas VR, Smith SK. The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstet Gynecol 1990; 76: 85-8.
69. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 1996; 313: 579-82.
70. Fraser IS, McCarron G, Markham R, Robinson M, Smyth E. Long-term treatment of menorrhagia with mefenamic acid. Obstet Gynecol 1983; 61: 109-12.
71. Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991; 164: 879-83.
72. Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol 1991; 31: 66-70.
73. Cameron IT, Leask R, Kelly RW, Baird DT. The effects of danazol, mefenamic acid, norethisterone and a progesterone-impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins 1987; 34: 99-110.
74. Guillebaud J, Anderson AB, Turnbull AC. Reduction by mefenamic acid of increased menstrual blood loss associated with intrauterine contraception. Br J Obstet Gynaecol 1978; 85: 53-62.
75. Callender ST, Warner GT, Cope E. Treatment of menorrhagia with tranexamic acid. A double-blind trial. Br Med J 1970; 4: 214-6.
76. Gleeson NC, Buggy F, Sheppard BL, Bonnar J. The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet Gynecol Scand 1994; 73: 274-7.
77. Edlund M, Andersson K, Rybo G, Lindoff C, Astedt B, von Schoultz B. Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi 2161). Br J Obstet Gynaecol 1995; 102: 913-7.
78. Lee JY, Hahn PM, Van Dijk JP, Reid RL. Treatment of menorrhagia with tranexamic acid. J Soc Obstet Gynaecol Can 2000; 22: 794-8.
79. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; 4: CD000249.
80. Irvine GA, Cameron IT. Medical management of dysfunctional uterine bleeding. Baillieres Best Pract Res Clin Obstet Gynaecol 1999; 13: 189-202.
81. Rydin E, Lundberg PO. Letter: Tranexamic acid and intracranial thrombosis. Lancet 1976; 2: 49.
82. Agnelli G, Gresele P, De Cunto M, Gallai V, Nenci GG. Tranexamic acid, intrauterine contraceptive devices and fatal cerebral arterial thrombosis. Case report. Br J Obstet Gynaecol 1982; 89: 681-2.
83. Rybo G. Tranexamic acid therapy; effective treatment in heavy menstrual bleeding. Therapeutic Adv 1991; 4: 1-8.
84. Ylikorkala O, Viinikka L. Comparison between anti-fibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. Br J Obstet Gynaecol 1983; 90: 78-83.
85. Chamberlain G, Freeman R, Price F, Kennedy A, Green D, Eve L. A comparative study of ethamsylate and mefenamic acid in dysfunctional uterine bleeding. Br J Obstet Gynaecol 1991; 98: 707-11.
86. Bishop PM, de Almeida JC. Treatment of functional menstrual disorders with norethisterone. Br Med J 1960; 1: 1103-5.
87. Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; 2: CD001016.
88. Preston JT, Cameron IT, Adams EJ, Smith SK. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol 1995; 102: 401-6.
89. Fraser IS. Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Aust N Z J Obstet Gynaecol 1990; 30: 353-6.
90. Irvine GA, Campbell-Brown MB, Lumsden MA, Heikkila A, Walker JJ, Cameron IT. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 1998; 105: 592-8.
91. Crosignani PG, Vercellini P, Mosconi P, Oldani S, Cortesi I, De Giorgi O. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. Obstet Gynecol 1997; 90: 257-63.
92. LahteenmakiP, Haukkamaa M, PuolakkaJ, Riikonen U, Sainio S et al. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. BMJ 1998; 316: 1122-6.
93. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova-T) IUCDs during five years use: a randomised comparative trial. Contraception 1994; 49: 56-72.
94. French R, Cowan F, Mansour D, Morris S, Hughes D et al. Hormonally impregnated intrauterine systems (IUSs), versus other forms of reversible contraceptives as effective methods of preventing pregnancy (Cochrane Review). Cochrane Database Syst Rev 2000; 2: CD001776.
95. Andersson K. The levonorgestrel intrauterine system: more than a contraceptive. Eur J Contracept Reprod Health Care 2001; 6: 15-22.
96. Lethaby AE, Cooke I, Rees M. Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; 2: CD002126.
97. Hurskainen R, Teperi J, Rissanen P, Aalto AM, Grenman S et al. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet 2001; 357: 273-7.
98. Iyer V, Farquhar C, Jepson R. Oral contraceptive pills for heavy menstrual bleeding. The Cochrane Library 2000; 2: CD000154.
99. Ramcharan S, Pellegrin FA, Ray RM, Hsu JP. The Walnut Creek Contraceptive Drug Study. A prospective study of the side effects of oral contraceptives, III, an interim report: a comparison of disease occurrence leading to hospitalization or death in users and non-users of oral contraceptives. J Reprod Med 1980: 25, 345-72.
100. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93.
101. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312: 83-8.
102. Lewis MA, MacRae KD, Kuhl-Habichl D, Bruppacher R, Heinemann LA, Spitzer WO. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 1999; 14: 1493-9.
103. Rees MC, Barlow DH. Quantitation of hormone replacement induced withdrawal bleeds. Br J Obstet Gynaecol 1991; 98: 106-7.
104. Barbieri RL. Danazol: molecular, endocrine, and clinical pharmacology. Prog Clin Biol Res 1990; 323: 241-52.
105. Need JA, Forbes KL, Milazzo L, McKenzie E. Danazol in the treatment of menorrhagia: the effect of a 1 month induction dose (200 mg) and 2 month's maintenance therapy (200 mg, 100 mg, 50 mg or placebo). Aust N Z J Obstet Gynaecol 1992; 32: 346-52.
106. Bonduelle M, Walker JJ, Calder AA. A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgrad Med J 1991; 67: 833-6.
107. Dockeray CJ, Sheppard BL, Bonnar J. Comparison between mefenamic acid and danazol in the treatment of established menorrhagia. Br J Obstet Gynaecol 1989; 96: 840-4.
108. Chimbira TH, Anderson AB, Cope E, Turnbull AC. Preliminary results on clinical and endocrine studies in the treatment of menorrhagia with danazol. Postgrad Med J 1979; 55: 90-4.
109. Higham JM, Shaw RW. A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. Am J Obstet Gynecol 1993; 169: 1134-9.
110. Turnbull AC, Rees MC. Gestrinone in the treatment of menorrhagia. Br J Obstet Gynaecol 1990; 97: 713-5.
111. Coutinho EM. Treatment of large fibroids with high doses of gestrinone. Gynecol Obstet Invest 1990; 30: 44-7.
112. Hipkin LJ. The induction of amenorrhoea. J R Army Med Corps 1992; 138: 15-8.
113. Moghissi KS. A clinician's guide to the use of gonadotropin-releasing hormone analogues in women. Medscape Womens Health 2000; 5: 5.
114. Friedman AJ, Hoffman DI, Comite F, Browneller RW, Miller JD. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group. Obstet Gynecol 1991; 77: 720-5.
115. Serra GB, Panetta V, Colosimo M, Romanini C, Lafuenti GB et al. Efficacy of leuprorelin acetate depot in symptomatic fibromatous uteri: the Italian Multicentre Trial. Clin Ther 1992; 14: 57-73.
116. Thomas EJ, Okuda KJ, Thomas NM. The combination of a depot gonadotrophin releasing hormone agonist and cyclical hormone replacement therapy for dysfunctional uterine bleeding. Br J Obstet Gynaecol 1991; 98: 1155-9.
117. Sowter MC, Singla AA, Lethaby A. Pre-operative endometrial thinning agents before hysteroscopic surgery for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; 2:CD001124.
118. Cadepond F, Ulmann A, Baulieu EE. RU486 (mifepristone). mechanisms of action and clinical uses. Annu Rev Med 1997; 48: 129-56.
119. Papp C, Schatz F, Krikun G, Hausknecht V, Lockwood CJ. Biological mechanisms underlying the clinical effects of mifepristone (RU 486) on the endometrium. Early Pregnancy 2000; 4: 230-9.
120. Brown A, Cheng L, Lin S, Baird DT. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab 2002; 87: 63-70.
121. Eldar-Geva T, Healy DL. Other medical management of uterine fibroids. Baillieres Clin Obstet Gynaecol 1998; 12: 269-88.
122. Kettel LM, Murphy AA, Morales AJ, Yen SS. Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum Reprod 1994; 9: 116-20.
123. Lepine LA, Hillis SD, Marchbanks PA, Koonin LM, Morrow B et al. Hysterectomy surveillance - United States 1980-1993. MMWR CDC Surveill Summ 1997; 46: 1-15.
124. Clarke A, Black N, Rowe P, Mott S, Howle K. Indications for and outcome of total abdominal hysterectomy for benign disease: a prospective cohort study. Br J Obstet Gynaecol 1995; 102: 611-20.
125. Dwyer N, Hutton J, Stirrat GM. Randomised controlled trial comparing endometrial resection with abdominal hysterectomy for the surgical treatment of menorrhagia. Br J Obstet Gynaecol 1993; 100: 237-43.
126. Dicker RC, Greenspan JR, Strauss LT, Cowart MR, Scally MJ et al. Complications of abdominal and vaginal hysterectomy among women of reproductive age in the United States. The Collaborative Review of Sterilization. Am J Obstet Gynecol 1982; 144: 841-8.
127. Reich H, Ribeiro SC, Vidali A. Hysterectomy as treatment for dysfunctional uterine bleeding. Baillieres Best Pract Res Clin Obstet Gynaecol 1999; 13: 251-69.
128. Wingo PA, Huezo CM, Rubin GL, Ory HW, Peterson HB. The mortality risk associated with hysterectomy. Am J Obstet Gynecol 1985; 152: 803-8.
129. Al-Took S, Platt R, Tulandi T. Adhesion-related small-bowel obstruction after gynecologic operations. Am J Obstet Gynecol 1999; 180: 313-5.
130. Olsen AL, Smith VJ, Bergstrom JO, CollingJC, Clark AL. Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynecol 1997; 89: 501-6.
131. Dennerstein L, Wood G, Burrows GD. Sexual dysfunction following hysterectomy. Aust Fam Physician 1977; 6: 535-43.
132. Rhodes JC, Kjerulff KH, Langenberg PW, Guzinski GM. Hysterectomy and sexual functioning. JAMA 1999; 282: 1934-41.
133. Siddle N, Sarrel P, Whitehead M. The effect of hysterectomy on the age at ovarian failure. identification of a subgroup of women with premature loss of ovarian function and literature review. Fertil Steril 1987; 47: 94-100.
134. Raven P, Lind C, Nilas L. Lack of influence of simple premenopausal hysterectomy on bone mass and bone metabolism. Am J Obstet Gynecol 1995; 172: 891-5.
135. Watson NR, Studd JW, Garnett T, Savvas M, Milligan P. Bone Loss after hysterectomy with ovarian conservation. Obstet Gynecol 1995; 86: 72-7.
136. Jones DE, Shackelford DP, Brame RG. Supracervical hysterectomy: back to the future? Am J Obstet Gynecol 1999; 180: 513-5.
137. Milad MP, Morrison K, Sokol A, Miller D, Kirkpatrick L. A comparison of laparoscopic supracervical hysterectomy vs laparoscopically assisted vaginal hysterectomy. Surg Endosc 2001; 15: 286-8.
138. Munro MG. Supracervical hysterectomy: a time for reappraisal. Obstet Gynecol 1997; 89: 133-9.
139. Soriano D, Goldstein A, Lecuru F, Darai E. Recovery from vaginal hysterectomy compared with laparoscopy-assisted vaginal hysterectomy: a prospective, randomized, multicenter study. Acta Obstet Gynecol Scand 2001; 80: 337-41.
140. Okaro EO, Jones KD, Sutton C. Long term outcome following laparoscopic supracervical hysterectomy. BJOG 2001; 108: 1017-20.
141. Garry R, Shelley-Jones D, Mooney P, Phillips G. Six hundred endometrial laser ablations. Obstet Gynecol 1995; 85: 24-9.
142. McAuliffe F, English J, Prendiville W. Patient satisfaction following transcervical resection of the endometrium. Ir J Med Sci 1996; 165: 170-2.
143. O'Connor H, Magos A. Long-Term Results of Endometrial Resection. J Am Assoc Gynecol Laparosc 1996; 3: S35.
144. Wortman M, Daggett A. Hysteroscopic endomyometrial resection. a new technique for the treatment of menorrhagia. Obstet Gynecol 1994; 83: 295-8.
145. Vercellini P, Oldani S, Yaylayan L, Zaina B, De Giorgi O, Crosignani PG. Randomized comparison of vaporizing electrode and cutting loop for endometrial ablation. Obstet Gynecol 1999; 94: 521-7.
146. Kim AH, Keltz MD, Arici A, Rosenberg M, Olive DL. Dilutional hyponatremia during hysteroscopic myomectomy with sorbitol-mannitol distention medium. J Am Assoc Gynecol Laparosc 1995; 2: 237-42.
147. Sculpher M, Thompson E, Brown J, Garry R. A cost effectiveness analysis of goserelin compared with danazol as endometrial thinning agents. BJOG 2000; 107: 340-6.
148. Hawe JA, Phillips AG, Chien PF, Erian J, Garry R. Cavaterm thermal balloon ablation for the treatment of menorrhagia. Br J Obstet Gynaecol 1999; 106: 1143-8.
149. Meyer WR, Walsh BW, Grainger DA, Peacock LM, Loffer FD, Steege JF. Thermal balloon and rollerball ablation to treat menorrhagia: a multicenter comparison. Obstet Gynecol 1998; 92: 98-103.
150. Grainger DA, Tjaden BL, Rowland C, Meyer WR. Thermal balloon and rollerball ablation to treat menorrhagia: two-year results of a multicenter, prospective, randomized, clinical trial. J Am Assoc Gynecol Laparosc 2000; 7: 175-9.
151. Loffer FD. Three-year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. J Am Assoc Gynecol Laparosc 2001; 8: 48-54.
152. Ulmsten U, Carstensen H, Falconer C, Holm L, Lanner L et al. The safety and efficacy of MenoTreat, a new balloon device for thermal endometrial ablation. Acta Obstet Gynecol Scand 2001; 80: 52-7.
153. Corson SL, Brill AI, Brooks PG, Cooper JM, Indman PD et al. One-year results of the vesta system for endometrial ablation. J Am Assoc Gynecol Laparosc 2000; 7: 489-97.
154. Romer T, Muller J, Foth D. Hydrothermal ablation. A new simple method for coagulating endometrium in patients with therapy-resistant recurring hypermenorrhea. Contrib Gynecol Obstet 2000; 20: 154-60.
155. Kochli OR. Endometrial ablation in the year 2000 - do we have more methods than indications? Contrib Gynecol Obstet 2000; 20: 91-120.
156. Munro MG. Dysfunctional uterine bleeding: advances in diagnosis and treatment. Curr Opin Obstet Gynecol 2001; 13: 475-89.
157. Donnez J, Polet R, Rabinovitz R, Ak M, Squifflet J, Nisolle M. Endometrial laser intrauterine thermotherapy. the first series of 100 patients observed for 1 year. Fertil Steril 2000; 74: 791-6.
158. Jones K, Abbott J, Hawe J, Sutton C, Garry R. Endometrial laser intrauterine thermotherapy for the treatment of dysfunctional uterine bleeding: the first British experience. BJOG 2001; 108: 749-53.
159. Cooper KG, Bain C, Parkin DE. Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss: a randomised trial. Lancet 1999; 354: 1859-63.
160. Hodgson DA, Feldberg IB, Sharp N, Cronin N, Evans M, Hirschowitz L. Microwave endometrial ablation, development, clinical trials and outcomes at three years. Br J Obstet Gynaecol 1999; 106: 684-94.
161. Tulandi T, Felemban A. Hysteroscopic appearance of the uterine cavity before and after microwave endometrial ablation. J Am Assoc Gynecol Laparosc 2001; 8: 83-6.
162. Rutherford TJ, Zreik TG, Troiano RN, Palter SF, Olive DL. Endometrial cryoablation, a minimally invasive procedure for abnormal uterine bleeding. J Am Assoc Gynecol Laparosc 1998; 5: 23-8.
163. Korn AP. Endometrial cryoablation and thermal ablation. Clin Obstet Gynecol 2000; 43: 575-83.
164. Kumar S, Suneetha PV, Dadhwal V, Mittal S. Endometrial cryoablation in the treatment of dysfunctional uterine bleeding. Int J Gynaecol Obstet 2002; 76: 189-90.
165. Van Vugt DA, Krzemien A, Roy BN, Fletcher WA, Foster W et al. Photodynamic endometrial ablation in the nonhuman primate. J Soc Gynecol Invest 2000; 7: 125-30.
166. Tadir Y, Hornung R, Pham TH, Tromberg BJ. Intrauterine light probe for photodynamic ablation therapy. Obstet Gynecol 1999; 93: 299-303.
167. Dwyer PJ, White WM, Fabian RL, Anderson RR. Optical integrating balloon device for photodynamic therapy. Lasers Surg Med 2000; 26: 58-66.
168. Seidman DS, Bitman G, Mashiach S, Hart S, Goldenberg M. The effect of increasing age on the outcome of hysteroscopic endometrial resection for management of dysfunctional uterine bleeding. J Am Assoc Gynecol Laparosc 2000; 7: 115-9.
169. McCausland AM, McCausland VM. Depth of endometrial penetration in adenomyosis helps determine outcome of rollerball ablation. Am J Obstet Gynecol 1996; 174: 1793-4.
170. Wortman M, Daggett A. Reoperative hysteroscopic surgery in the management of patients who fail endometrial ablation and resection. J Am Assoc Gynecol Laparosc 2001; 8: 272-7.
171. Eskandar MA, Vilos GA, Aletebi FA, Tummon IS. Hysteroscopic endometrial ablation is an effective alternative to hysterectomy in women with menorrhagia and large uteri. J Am Assoc Gynecol Laparosc 2000; 7: 339-45.
172. Jansen FW, Vredevoogd CB, van Ulzen K, Hermans J, Trimbos JB, Trimbos-Kemper TC. Complications of hysteroscopy: a prospective, multicenter study. Obstet Gynecol 2000; 96: 266-70.
173. Overton C, Hargreaves J, Maresh M. A national survey of the complications of endometrial destruction for menstrual disorders: the MISTLETOE study. Minimally Invasive Surgical Techniques - Laser, EndoThermal or Endorescetion. Br J Obstet Gynaecol 1997; 104: 1351-9.
174. Bhattacharya S, Cameron IM, Parkin DE, Abramovich DR, Mollison J, Pinion SB et al. A pragmatic randomised comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia. Br J Obstet Gynaecol 1997; 104: 601-7.
175. Ismail MS, Torsten U, Serour GI, Weitzel H, Berlien HP. Is endometrial ablation a safe contraceptive method? Pregnancy following endometrial ablation. Eur J Contracept Reprod Health Care 1998; 3: 99-102.
176. Pugh CP, Crane JM, Hogan TG. Successful intrauterine pregnancy after endometrial ablation. J Am Assoc Gynecol Laparosc 2000; 7: 391-4.
177. Valle RF, Baggish MS. Endometrial carcinoma after endometrial ablation: high-risk factors predicting its occurrence. Am J Obstet Gynecol 1998; 179: 569-72.
178. Brooks-Carter GN, Killackey MA, Neuwirth RS. Adenocarcinoma of the endometrium after endometrial ablation. Obstet Gynecol 2000; 96: 836-7.
179. Lethaby A, Shepperd S, Cooke I, Farquhar C. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; 2: CD000329.
180. Aberdeen Endometrial Ablation Trials Group . Randomised trial of endometrial ablation versus hysterectomy for the treatment of dysfunctional uterine bleeding: outcome at four years. Br J Obstet Gynaecol 1999; 106: 360-6.
181. Bridgman SA, Dunn KM. Has endometrial ablation replaced hysterectomy for the treatment of dysfunctional uterine bleeding? National figures. BJOG 2000; 107: 531-4.